Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve T...(tive antihypertensives): dizziness...),Health

antihypertensives): dizziness (10.2% vs 6.0%), orthostatic dizziness

(5.4% vs 2.7%) and orthostatic hypotension (5.4% vs 3.2%),

respectively. In patients with proteinuria, monitor serum potassium

-- In placebo-controlled hypertension studies, the most common adverse

experiences reported with AVALIDE that occurred in greater than or

equal to 1% of patients and at a higher incidence vs placebo included

fatigue (7% vs 3%), musculoskeletal pain (7% vs 5%), dizziness (8% vs

4%), and nausea/vomiting (3% vs 0%). Additionally, in studies of

moderate and severe hypertensives where AVALIDE was used as initial

therapy, the types and incidences of adverse events reported for

AVALIDE were similar to monotherapy

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY)

About Bristol-Myers Squibb

For more than 40 years, Bristol-Myers Squibb has been committed to building a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists in Bristol-Myers Squibb's Research & Development organization are studying ways to improve current cancer treatments and identify better, more effective medicines for the future. Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human
'/>"/>